



RECEIVED

4P/611

MAY 10 2002

TECH CENTER 1600/2900

RECEIVED

FEB 19 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fred S. Lamb

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALY-COMPROMISED VASCULAR SMOOTH MUSCLE

Docket No.: 875.039US1

Serial No.: 09/512,926

Filed: February 25, 2000

Due Date: January 10, 2002

Examiner: Jennifer Kim

Group Art Unit: 1617

**BOX NON-FEE AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

- A return postcard.  
 An Amendment and Response Under 37 CFR 1.111 (9 Pages).  
 Clean Version of Pending Claims (4 pgs.).  
 Declaration Under 37 CFR 1.132 of A. Dunbar, including Appendix A (2 pgs.).

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By:   
Atty: Ann S. Viksnins  
Reg. No. 37,748

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: BOX NON-FEE AMENDMENT, Commissioner for Patents, Washington, D.C. 20231, on this 9/12 day of January, 2002.

Candis B. Buending

Name

Signature

**Customer Number 21186**

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)  
(GENERAL)



RECEIVED  
FEB 19 2002  
TECH CENTER 1600  
PATENT 1600/2000  
#15/13  
JAN 10 2002  
5/17/02

S/N 09/512,926

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fred S. Lamb

Examiner: Jennifer Kim

Serial No.: 09/512,926

Group Art Unit: 1617

Filed: February 25, 2000

Docket: 875.039US1

Title: METHODS TO REDUCE THE SENSITIVITY OF ENDOTHELIALY-COMPROMISED VASCULAR SMOOTH MUSCLE

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Office Action mailed on October 10, 2001. Please amend the above-identified application as follows:

In the Claims

Please substitute the claim set, attached hereto, entitled "Clean Version of Pending Claims" for the previously pending claim set. The specific amendments to individual claims are detailed in the following marked up set of claims.

Please cancel claims 2, 5, and 12.

Please amend the claims as follows:

3. (Amended) A method of claim 22 [2], wherein the compound administered is 1-p- $\beta$ -dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene [(tamoxifen)], or a pharmaceutically acceptable salt thereof.
4. (Amended) A method to ameliorate the negative effects associated with vascular smooth muscle endothelium damage in a patient [is] in need of such treatment, comprising administering a pharmaceutically effective amount of a CLC3 blocker, or a pharmaceutically acceptable salt thereof.